Recall of B. Braun Hemodialysis Bloodlines Due to Potential Air Bubble Risk

Source: FDA · United States

B Braun Medical Inc is recalling 1,174,271 units of its Hemodialysis Bloodlines because of a potential for air bubbles in the arterial line, affecting products distributed nationwide in the US and Canada.

What this FDA recall tells you, and what most readers miss

This notice was issued by FDA on May 4, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Devices) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

What Happened

B Braun Medical Inc has initiated a recall due to the potential for the accumulation of small air bubbles in the arterial line of the hemodialysis bloodlines, caused by adherence of blood gases to the tubing under negative pressure.

Which Products Are Affected

The affected product is B. Braun Hemodialysis Bloodlines, STREAMLINE FRESENIUS FOR DAVITA, with Model Number: SL-2000M2095DA. A total of 1,174,271 units are involved, including all lots manufactured since 09JUN2025. The product has UDI-DI Primary: 04046955776023 and UDI-DI Unit: 04046955776016. Distribution occurred nationwide in the United States and in Canada.

What You Should Do

Consumers should follow the initial firm notification, which was issued via letter, for instructions on how to proceed with the recall initiated by B Braun Medical Inc.

Why This Matters

This recall involves over a million units of a medical device used in hemodialysis, highlighting potential risks in patient treatment due to the air bubble issue.

Source

From FDA recall notice for event ID 98552 and recall number Z-1800-2026.

Original source: FDA Official Notice ↗

Related FDA Recalls

All FDA Recalls →

Frequently Asked Questions

Common questions about this FDA recall.

What is this FDA recall about?
B Braun Medical Inc is recalling 1,174,271 units of its Hemodialysis Bloodlines because of a potential for air bubbles in the arterial line, affecting products distributed nationwide in the US and Canada.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "high" severity. Take precautions and monitor for updates.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates?
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.